Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dalteparin's Influence on Renally Compromised: Anti-Ten-A Study (DIRECT)

NCT00138099 is registered in ClinicalTrials.gov with Hamilton Health Sciences Corporation as lead sponsor.

NCT NCT00138099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00138099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dalteparin's Influence on Renally Compromised: Anti-Ten-A Study (DIRECT)
Lead sponsor
Hamilton Health Sciences Corporation
Phase
Observational
Overall status
Completed
Start date
July 31, 2004
Completion date
June 30, 2006
Enrollment
140 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

renal insufficiency